U.S. FDA issues two observations to Cipla arm InvaGen’s U.S. facility

The observations followed a pre-approval inspection (PAI) by the regulator at InvaGen's manufacturing facility in Hauppauge, Long Island, New YorkThe observations followed a pre-approval inspection (PAI) by the regulator at InvaGen's manufacturing facility in Hauppauge, Long Island, New York https://www.thehindu.com/business/Industry/us-fda-issues-two-observations-to-cipla-arm-invagens-us-facility/article70613952.ece 2026-02-10T05:53:29.000Z Industry {}